论文部分内容阅读
目的探讨腹腔注射内皮抑素腺病毒治疗裸鼠原位胰腺癌的机制,观测其疗效。方法通过细胞内同源重组方法构建携带内皮抑素重组腺病毒Ad-mEndo,体外转染胰腺癌细胞株AsPC-1、BxPC-3,并测定感染的胰腺癌细胞上清液(鼠源性内皮抑素)mEndostatin蛋白的表达。荷瘤裸鼠腹腔注射腺病毒液Ad-mEndo,观察原位胰腺癌肿瘤的大小及测定肿瘤微血管密度。结果重组腺病毒Ad-mEndo体外能转染胰腺癌细胞株,并表达mEndostatin mRNA及蛋白。重组腺病毒Ad-mEndo治疗组肿瘤体积和微血管密度均显著小于生理盐水组,差异均有高度统计学意义(均P<0.01)。结论重组腺病毒Ad-mEndo腹腔注射能有效抑制裸鼠原位胰腺癌的生长,为胰腺癌的治疗探索了一种新的治疗途径。
Objective To investigate the mechanism of intraperitoneal injection of endostatin adenovirus for pancreatic cancer in situ in nude mice and observe its curative effect. Methods Recombinant adenovirus carrying endostatin (Ad-mEndo) was constructed by intracellular homologous recombination and transfected into pancreatic cancer cell lines AsPC-1 and BxPC-3 in vitro. The supernatant of infected pancreatic cancer cells Endostatin) expression of mEndostatin protein. The tumor-bearing nude mice were injected intraperitoneally with adenovirus Ad-mEndo to observe the size of the tumors in situ and to determine the tumor microvessel density. Results The recombinant adenovirus Ad-mEndo transfected pancreatic cancer cell lines in vitro and expressed mEndostatin mRNA and protein. The tumor volume and microvessel density of recombinant adenovirus Ad-mEndo treatment group were significantly lower than that of saline group, the differences were statistically significant (all P <0.01). Conclusion Intraperitoneal injection of recombinant adenovirus Ad-mEndo can effectively inhibit the growth of in situ pancreatic cancer in nude mice and explore a new therapeutic approach for the treatment of pancreatic cancer.